peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update

30 Jun 2022, 08:00

Lund, Sweden June 30, 2022 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2022 at 8:00 CET on July 19, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

The webcast will be available on

Participant access code: 729818

Updated Calendar and Events 2022

July 19, 2022                         Half year 2022 report 

Aug 9, 2022      BTIG Biotechnology Conference 2022, New York

Aug 10, 2022  Canaccord Annual Growth Conference, Boston

Aug 11-12, 2022 Kempen US non-deal road show

Aug 18, 2022  Penserpodden ”Focus on autoimmunity” (virtual)

Aug 31, 2022  Redeye Late Stage Life Science conference, Stockholm

Sept 7, 2022  Pareto annual Healthcare Conference 2022, Stockholm

Sept 7-8, 2022                     Citi's 17th Annual BioPharma Conference, Boston

Sept 12-14, 2022 MorganStanley Global Healthcare Conference, New York

Sept 20, 2022  Redeye Afterwork presentation, Gothenburg

Sept 21, 2022  Redeye Lunch presentation, Stockholm

Sept 26, 2022  Aktiespararna Aktiedagen, Lund

Oct 20, 2022  Interim Report for January-September 2022

Nov 23, 2022  Økonomisk Ugebrev Life Science Conference, Copenhagen

Nov 24, 2022  Redeye Life Science Day, Stockholm

Dec 1, 2022  Erik Penser Banks Temadag - Health Care, Stockholm

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at